Operator
Good morning, ladies and gentlemen. Thank you for joining us for TherapeuticsMD first-quarter 2020 financial results conference call. [Operator instructions] I would now like to turn the call over to TherapeuticsMD s vice president of investor relations, Nichol Ochsner. Nichol?
Nichol Ochsner
Vice President, Investor Relations
Good morning, everyone. Thank you for joining today to discuss our first-quarter financial results and business update. This morning, TherapeuticsMD issued a press release announcing our first-quarter financial results. The press release is available on the company s website therapeuticsmd.com and the Investors and Media section.
On today s call from TherapeuticsMD are Chief Executive Officer Robert Finizio, Chief Financial Officer James D Arecca, Chief Commercial Officer Dawn Halkuff, and Chief Strategy and Performance Officer Mitchell Krassan. I would like to remind everyone that certain statements made during this conference call may be forw
Operator
Good morning, ladies and gentlemen. Thank you for joining us for TherapeuticsMD fourth-quarter 2020 financial results conference call. [Operator instructions] I would now like to turn the call over to TherapeuticsMD s Vice President of Investor Relations Nichol Ochsner. Nichol?
Nichol Ochsner
Vice President, Investor Relations
Thank you. Good morning, everyone. Thank you for joining today to discuss our fourth-quarter financial results and business update. This morning, TherapeuticsMD issued a press release announcing our fourth-quarter financial results.
The press release is available on the company s website, therapeuticsmd.com in the investors and media section. On today s call from TherapeuticsMD are Chief Executive Officer Robert Finizio, Chief Financial Officer James D Arecca, Chief Commercial Officer Dawn Halkuff, and Chief Strategy and Performance Officer Mitchell Krassan. I would like to remind everyone that certain statements made during this conference cal